Education, Research, and Quality Improvement: Education, Research, and Quality Improvement II |

Improving Measures of Knowledge, Attitudes, and Practices Related to Cystic Fibrosis Health in Patients, Providers, and Caregivers Using CareMessage FREE TO VIEW

Joseph Papador, BA; Chris Landon, MD; Preston Arndt, MD; Ralph Turner, PhD
Author and Funding Information

Ventura County Medical Center, Ventura, CA

Copyright 2016, American College of Chest Physicians. All Rights Reserved.

Chest. 2016;150(4_S):616A. doi:10.1016/j.chest.2016.08.708
Text Size: A A A
Published online

SESSION TITLE: Education, Research, and Quality Improvement II

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM

PURPOSE: Cystic Fibrosis is a chronic, autosomal recessive disorder that requires treatment with complex medical regiments and specialized diets. Adherence to these treatment plans remains discouragingly low, with a rate ranging between 31-53% for inhaled antibiotics. Educational programs are being developed to increase the knowledge, attitudes and practices of Cystic Fibrosis patients, providers and caregivers. CareMessage is a text messaging service that utilizes a database of questions and statements to send messages to a designated population, and to send prewritten feedback based on the responses given.

METHODS: The Cystic Fibrosis CareMessage database can be uniquely modified to create a program targeting a given group or individual participant that the messages will be sent to. The IRB reviewed assent and consent issues. A focus group, consisting of patients with Cystic Fibrosis, their parents and the Pediatric Diagnostic Center's CF team, was used to identify the greatest learning needs of our targeted populations. Patients and their families were consulted in clinic during their CF team visits and of clinic using SurveyMonkey. The CF team was consulted during a post-clinic meeting. The CareMessage programs for COPD and Diabetes were reviewed for messages that crossover into Cystic Fibrosis health. Along with this educational portion of CareMessage, patients will also be sent appointment reminders for visits with the CF team and their Pediatric Pulmonologist, medication refill, daily medication reminders if adherence issues have emerged and the patient has agreed to this intervention, and notices of educational events. Participants are enrolled into the program during their visits with the CF team.

RESULTS: Based on the data collected from our patient population, the Cystic Fibrosis related topics that are most important to the needs of our patients include nutrition, exercise, disease information and adherence. Messages in the Cystic Fibrosis CareMessage database will be catered to enhance education in these topics. Feedback from the CF team revealed a reluctance from providers to participate in educational programs such as CareMessage. Fifty eight questions from the COPD and Diabetes programs have been identified and integrated into the Cystic Fibrosis database. Eighteen patients have been enrolled into the Cystic Fibrosis CareMessage program to date.

CONCLUSIONS: Based on the need to increase adherence to Cystic Fibrosis treatments and the feedback that was received from the patients, the program will begin with messages relating to adherence. Adherence messages, taken from the Morisky Adherence Questionnaire, have been implemented into the CareMessage system and are being sent to patients. A goal of 150 participants including patients, providers and caregivers has been set for the Cystic Fibrosis CareMessage program.

CLINICAL IMPLICATIONS: This program has the potential to increase measures of knowledge, attitudes and practices in Cystic Fibrosis health. It will allow for providers to have a better understanding of their patient's education needs, and give them another measurement of their patient's adherence. CareMessage can also be used, in clinic, to send appointment reminders and receive confirmations from the patients for each visit.

DISCLOSURE: The following authors have nothing to disclose: Joseph Papador, Chris Landon, Preston Arndt, Ralph Turner

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543